Robert William Azelby
Independent Chairman of the BoardMr. Robert William Azelby, also known as Bob, M.B.A., is Independent Director of Tango Therapeutics, Inc. from June 19, 2026 and also serves as Chairman Since August 6, 2026. He was Independent Director at Terns Pharmaceuticals, Inc. from February 20, 2025 until May 4, 2026. He serves as Independent Non-Executive Director at Autolus Therapeutics plc since January 09, 2024. Mr. Azelby is a biopharmaceutical executive and experienced public company director with vast industry leadership spanning executive management, commercial strategy, oncology product launches and corporate governance. He ahs vast leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board governance. He serves as Independent Director at ADC Therapeutics SA since June 14, 2023. He served as Independent Director at Chinook Therapeutics, Inc. since April 2023 until August 11, 2023. He served as the President and Director at Eliem Therapeutics, Inc. until February 10, 2023 and served as its Chief Executive Officer since October 2020 until February 10, 2023. He has been an Independent Director of Clovis Oncology, Inc since October 11, 2018. He served as an Independent Director of Immunomedics Incorporated since February 26, 2020 until October 23, 2020. He served as Chief Executive Officer, President and Director of Alder Bio Pharmaceuticals, Inc. since June 13, 2018 until October 22, 2019. Mr. Azelby served as Chief Commercial Officer and Executive Vice President of Juno Therapeutics Incorporated since November 2, 2015 to May 2018. Prior to joining Juno in 2015, he served as Vice President of Amgen’s North American Commercial Effectiveness Unit and was responsible for sales and marketing functions, including market research, forecasting, sales training and sales operations. He worked at Amgen Inc. where he served as Vice President and General Manager of Amgen’s Oncology Business Unit since June 2012 to October 2015. He joined Amgen Inc. in 2000. During his tenure at Amgen, he served as Vice President of Amgen’s U.S. Oncology Sales team from October 2010 to May 2012, which was one of the largest oncology sales teams in the U.S. He garnered international experience as Amgen’s General Manager, Netherlands, responsible for all aspects of its commercial operations in that country From June 2012 to October 2015. Mr. Azelby has biopharmaceutical industry expertise. He held numerous sales and marketing positions, each with increasing responsibilities. His roles included project management, business development, regional sales management and national marketing Director. He began his career in the industry as a sales Representative in Philadelphia for the former British drug company Glaxo Welcome PLC. He then worked for Oxford Health Plans, a subsidiary of the healthcare organization Oxford Health and the medical risk management start-up Avandel Inc. before joining Amgen. He has been Director of Alliance for Regenerative Medicine since 2018. He serves as Independent Director at Cardinal Health, Inc. from March 01, 2024. He served as a Director of Cascadian Therapeutics, Incorporated from April 2017 to March 9, 2018. He is a biotechnology and pharmaceutical industry veteran. Mr. Azelby received his bachelor’s degree (B.A) in Economics and Religious Studies from University of Virginia and his Master of Business Administration from Harvard Business School.
Positions
- Company NameTango Therapeutics, Inc.Stock CodeTNGXPositionIndependent Chairman of the BoardColleagues
- MPMalte PetersPresident, CEO & Director
- BLBarbara L. WeberExecutive Officer
- ASAdam S. CrystalPresident of Research & Development
- AAAlan AshworthFounder & Member of Scientific Advisory Board
- WGWilliam G. KaelinFounder & Member of Scientific Advisory Board
- ARAntoni RibasFounder & Member of Scientific Advisory Board
